Uncategorized
Dextenza meets one of two primary endpoints in phase 3 allergic conjunctivitis clinical trial
Dextenza has met the primary endpoint for treating ocular itching associated with allergic conjunctivitis in a phase 3 clinical trial, Ocular Therapeutix announced in a press release. For ocular itching, the Dextenza (sustained-release dexamethasone 0.4 mg) group showed a mean score of greater than 0.5 units at all time points and greater than 1 unit at a majority of the time points on day 7 after insertion compared with a placebo group (P < .0001) .